Windward Bio Closes IPO and Placement With $251.2M, Sanofi In for $50M
WWB sits 64% above its 52-week low of $18.35 on light trading volume (0.3× avg).
Summary
Windward Bio closed its IPO and concurrent private placement, raising about $251.2M in gross proceeds. The IPO closed on 11,838,234 shares at $17.00, including full exercise of 1,544,117 option shares, for $201.2M. Sanofi Foreign Participations separately bought $50.0M of shares and pre-funded warrants — a strategic investor taking a meaningful stake alongside the public offering; the placement covered 1,532,691 shares and 1,408,485 pre-funded warrants. This follows the Nov. 12 pricing of 10.3 million shares at $17 that was expected to raise roughly $175M before fees; the final total is larger because it includes the placement and the full option exercise. The company is now public with a funded balance sheet, but its clinical-stage programs are still under evaluation. Readouts from the POLARIS-1, SIRIUS and WIN027 studies are the next things that will move the stock.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — Windward Bio's IPO closed on 11,838,234 shares at $17.00, including full exercise of 1,544,117 option shares, for $201.2M; the Sanofi placement covered 1,532,691 shares and 1,408,485 pre-funded warrants for $50.0M.
At the time of this announcement, WWB was trading at $30.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $18.35 to $33.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.